Biotech strategy update — see how a company is positioning complementary therapeutic platforms to broaden treatment options for inflammatory and fibrotic diseases.
Key Takeaways
- Material transfer agreements were signed with independent LNP providers for in vivo myeloid engineering
- Systematic parallel assessments of LNP vehicles will run while proprietary mRNA payloads are finalized
- Preliminary LNP assessment results and interim clinical data are expected later this year